At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
SNS-595 Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating SNS-595 Injection for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 31 participants across 4 sites.
Detailed Summary
The purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartDec 2005
Primary CompletionMar 2007
Study CompletionNov 2007
TodayJul 2026
First PostedNov 11, 2005
Enrollment StartDec 27, 2005
Primary CompletionMar 5, 2007
Study CompletionNov 29, 2007
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.6 years ago
Interventions
SNS-595 Injectiondrug
Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.